Check back soon.

We’re currently working on updating all our web assets. We thank you for your patience. In the meantime, please visit our global site or check news and updates on our social media channels.

Company details


Company number: 9622645

Board members
Dr Lorna Meldrum, Mark Sullivan, Kate Antrobus, Dr Michael Elliot, Prof Andrew Wilks

Contact
Medicines Development for Global Health Limited
C/O BCS Windsor House, Station Court, Station Road, Great Shelford,
Cambridge, CB22 5NE, United Kingdom

What we do
Medicines Development for Global Health Limited develops medicines for neglected diseases that primarily affect people living in poverty. It is an affiliate of Medicines Development for Global Health (MDGH Australia), an independent biopharmaceutical company incorporated in Australia (Australian Company Number 116 977 523) and registered as a charity with the Australian Charities and Not-for-Profits Commission.

MDGH’s mission is to address health inequity by putting new and improved medicines into the hands of people who need them most while its core expertise is in the development of medicines to rigorous regulatory standards.

In 2019 and 2021, the European & Developing Countries Clinical Trials Partnership (EDCTP) provided two substantial grants to Medicines Development for Global Health Limited and partners: €4.6m for additional clinical trials comparing efficacy and safety of single or annual and biannual moxidectin or ivermectin treatment (EDCTP Grant 1), and €2.8m for the development of a paediatric formulation of moxidectin (EDCTP Grant 2).

See project information at https://mox4oncho-multimox.net

———
Medicines Development for Global Health Limited was incorporated as a company limited by guarantee on 3 June 2015. The company is in the process of applying for registration as a charity with the UK Charities Commission.